South San Francisco, CA May 7, 2019 Genentech Press Release Genentech Presents Data from the Risdiplam Pivotal FIREFISH and SUNFISH Studies in Spinal Muscular Atrophy at the 2019 AAN Annual Meeting In the dose-finding Part 1 of FIREFISH, infants with…
Tag: biopharmaceutical
New Genentech Data at the 2019 AAN Annual Meeting Showcase Breadth and Promise of Neuroscience Portfolio
South San Francisco, CA April 29, 2019 Genentech Press Release Risdiplam data from Part 1 of pivotal FIREFISH study show infants with Type 1 spinal muscular atrophy achieve key motor milestones and improved survival after one year of treatment New…
Genentech Submits Supplemental Biologics License Application to FDA; Breast Cancer
South San Francisco, CA February 8, 2019 Genentech Press Release Genentech Submits Supplemental Biologics License Application to FDA For Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment — Application is being…
Cancer Research Institute Celebrates Sixth Annual Cancer Immunotherapy Month™ in June
South San Francisco, CA June 21, 2018 by Cancer Research Institute 30 days of education and awareness programming for patients, caregivers, and the public about cancer immunotherapy and clinical trials Join in #WearWhite Day on Friday, June 15, our signature…
Phase III IMpower150 Study Showed Genentech’s Tecentriq (Atezolizumab) and Avastin (Bevacizumab) Plus Chemotherapy Significantly Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with a Type of Advanced Lung Cancer
South San Francisco, CA November 29, 2017 Genentech Press Release – Data will be submitted to health authorities globally, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) – SOUTH SAN FRANCISCO, CA — 2017-11-19 00:00:00 Genentech,…
Genentech’s Hemlibra (Emicizumab-kxwh) Significantly Reduced Bleeds in Phase III Study in Hemophilia A
South San Francisco, CA November 29, 2017 Genentech Press Release HAVEN 3 study met primary endpoint and key secondary endpoints Intra-patient comparison demonstrated superiority of HEMLIBRA prophylaxis compared to prior factor VIII prophylaxis SOUTH SAN FRANCISCO, CA — 2017-11-19 00:00:00…
Everything South City Welcomes Genewiz to South San Francisco’s ‘Biotech Ecosystem’
South San Francisco, CA November 10, 2017 by Mel Ellison, ESC Correspondent This past Thursday, South San Francisco welcomed biotech company Genewiz, into the growing cluster of such companies in our city, with a ribbon cutting ceremony…
Tricida Announces Closing of $57.5 Million Series D Financing
South San Francisco, CA November 8, 2017 Tricida, Inc Press Release SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tricida, Inc., a Phase 3 stage biopharmaceutical company focused on the discovery and development of non-absorbed oral drug therapies, today announced the closing of an oversubscribed…